Mati Therapeutics Inc.

Qlt Inc.

Retinagenix Therapeutics, Inc.

Novelion Therapeutics Inc.

Retinagenix, LLC

Retinagenix Holdings LLC

Suzanne Cadden

H Andrew Strong

Valery Rubinchik

Ronald Erwin Boch

Deepank Utkhede

Yong Hao

Charles Richard Kjellbotn

Charles Richard Kjelbotn

Disclosed herein are therapeutic regimens for improving visual function in Retinitis Pigmentosa and other visual disorders associated with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative, for example a 9- or 11-cis retinyl ester, according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.

Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through a firsts punctum and into a first lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a second punctum and into a second lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Sustained release delivery of active agents to treat glaucoma and ocular hypertension

Disclosed herein are therapeutic regimens for treating or ameliorating a visual disorder associate with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative or a pharmaceutically acceptable composition comprising a synthetic retinal derivative according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.

Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency

A method of decreasing intraocular pressure (IOP) in an eye of a patient in need thereof includes implanting a first lacrimal implant through an upper punctum and into an upper lacrimal canaliculus of the eye of the patient. The method may further comprise implanting a second lacrimal implant through a lower punctum and into a lower lacrimal canaliculus of the eye of the patient, and releasing, on a sustained basis a therapeutically effective amount of an intraocular pressure-reducing therapeutic agent.

Drug delivery system and methods of treating open angle glaucoma and ocular hypertension

Growing community of inventors

Vancouver, Canada

Suzanne Cadden